PROCUREMENT AND LATE-STAGE DEVELOPMENT OF SMALLPOX ANTIVIRAL DRUG(S) IGF::OT::IGF
Key facts
| Status | Awarded |
|---|---|
| Estimated value | $626,506,870 |
| Submission deadline | Deadline not published |
| Published | Sep 10, 2018 |
| Buyer | Office of Assistant Secretary for Preparedness and Response |
| Country | United States · OR |
| CPV code | NAICS 541714 (RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTEC) · PSC AN13 |
| Source | USAspending.gov Federal Contract Awards ↗ |
- Status
- Awarded
- Estimated value
- $626,506,870
- Submission deadline
- Deadline not published
- Published
- Sep 10, 2018
- Country
- United States
- CPV code
- NAICS 541714 (RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTEC) · PSC AN13
- Source
- USAspending.gov Federal Contract Awards
Contract outcome & evergreen alternatives
This notice is no longer open for submissions. The original remains available for reference.
| Awarded supplier / winner | Registration / LEI number | Country | Awarded contract amount | Award date |
|---|---|---|---|---|
| SIGA TECHNOLOGIES, INC. | US-UEI: VJRNRTSL22K4 | United States | $626,506,870 | Sep 10, 2018 |
Checked:
The original notice takes precedence. Its status and conditions can change after collection.
Description
PROCUREMENT AND LATE-STAGE DEVELOPMENT OF SMALLPOX ANTIVIRAL DRUG(S) IGF::OT::IGF
Awarding Agency: Department of Health and Human Services — Office of Assistant Secretary for Preparedness and Response.
NAICS 541714: RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY).
PSC AN13: HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT.
Period of Performance: 2018-09-10 to 2029-08-30.